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MaOBJECTIVES The aim of this study was to investigate the hypothesis that a novel biodegradable polymer–coated,
cobalt-chromium (CoCr), sirolimus-eluting stent (BP-SES) is noninferior in safety and efﬁcacy outcomes compared with
a durable polymer (DP)-SES.
BACKGROUND No randomized trials have the compared safety and efﬁcacy of BP-SES versus DP-SES on similar
CoCr platforms, thereby isolating the effect of the polymer type.
METHODS In this prospective, single-blind, randomized trial conducted at 32 Chinese sites, 2,737 patients eligible for
coronary stenting were treated with BP- or DP-SES in a 2:1 ratio. The primary endpoint was 12-month target lesion failure
(TLF), a composite of cardiac death, target vessel myocardial infarction, or clinically indicated target lesion revascular-
ization. Secondary endpoints included TLF components, and deﬁnite/probable stent thrombosis.
RESULTS At 12 months, the difference in the primary endpoint of TLF between BP-SES (6.3%) and DP-SES (6.1%)
groups was 0.25% (95% conﬁdence interval: 1.67% to 2.17%, p for noninferiority ¼ 0.0002), demonstrating nonin-
feriority of BP-SES to DP-SES. Individual TLF components of cardiac death (0.7% vs. 0.6%, p ¼ 0.62), target vessel
myocardial infarction (3.6% vs. 4.3%, p ¼ 0.39), and clinically indicated target lesion revascularization (2.6% vs.
2.2%, p ¼ 0.50) were similar, as were low deﬁnite/probable stent thrombosis rates (0.4% vs. 0.6%, p ¼ 0.55).
CONCLUSIONS In this large-scale real-world trial, BP-SES was noninferior to DP-SES for 1-year TLF. (Evaluate
Safety and Effectiveness of the Tivoli  DES and the Firebird  DES for Treatment of Coronary Revascularization;
NCT01681381) (J Am Coll Cardiol Intv 2014;7:1352–60) © 2014 by the American College of Cardiology Foundation.D rug-eluting stents (DES) using biodegrad-able polymers (BPs) have been designedto overcome long-term adverse vascular
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TABLE 1 Comparison of BP-SES, DP-SES, and Cypher SES Speciﬁcations
BP-SES DP-SES Cypher SES
Stent platform material Cobalt-chromium
(L605)
Cobalt-chromium
(L605)
Stainless steel (316L)
Strut thickness, mm 0.080 0.086 0.140
Stent proﬁle, mm <1.10 <1.12 <1.30
Diameter, mm 2.50, 2.75, 3.00,
3.50, 4.00
2.50, 2.75, 3.00,
3.50, 4.00
2.50, 2.75, 3.00,
3.50
Length, mm 10, 15, 18, 21, 25, 30, 35 13, 18, 23, 29, 33 8, 13, 18, 23, 28, 33
Drug Sirolimus Sirolimus Sirolimus
Drug dose, mg/mm 8.0 9.0 8.3
Polymer PLGA (biodegradable) SBS (durable) PEVA/PBMA (durable)
Polymer thickness, mm 5.5 6.0 12.6
Drug release 75% at 28 days >80% at 30 days 80% at 28 days
BP-SES ¼ biodegradable polymer sirolimus-eluting stent; DP-SES ¼ durable polymer sirolimus-eluting stent;
PBMA ¼ poly-n-butyl methacrylate; PEVA ¼ polyethylene-co-vinyl acetate; PLGA ¼ polylactide-co-glycolide;
SBS ¼ styrene-butadiene block copolymer.
AB BR E V I A T I O N S
AND ACRONYM S
BP = biodegradable polymer
CoCr = cobalt-chromium
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
DP = durable polymer
MI = myocardial infarction
PCI = percutaneous coronary
intervention
SES = sirolimus-eluting
stent(s)
TLF = target lesion failure
TLR = target lesion
revascularization
TVMI = target vessel
myocardial infarction
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1353reductions in clinical outcomes remains unsettled.
We previously demonstrated a satisfactory safety
proﬁle of BP-DES with low rates of overall stent
thrombosis (4). Similarly, a pooled analysis of the
ISAR TEST-3 (Rapamycin-Eluting Stents With
Different Polymer Coating to Reduce Restenosis)
ISAR TEST-4 (3 Limus Agent Eluting Stents With
Different Polymer Coating), and LEADERS (Limus
Eluted from A Durable versus ERodable Stent coating)
trial showed that BP-DES were associated with a
signiﬁcantly lower rate of very late deﬁnite stent
thrombosis from 1 to 4 years compared with DP-DES
(5). However, the recent SORT OUT V (Scandinavian
Organization for Randomized Trials with Clinical
Outcome) trial reported that BP biolimus-eluting
stents did not show noninferiority compared with
DP sirolimus-eluting stents (SES) at 1-year follow-up
(6). No randomized trials have compared safety and
efﬁcacy of BP-SES versus DP-SES on similar cobalt-
chromium (CoCr) platforms, thereby isolating the ef-
fect of the BP from other stent-related effects. We
therefore designed a large-scale randomized trial
comparing a novel CoCr BP-SES (TIVOLI, EssenTech,
Beijing, China) and the CoCr DP-SES (FIREBIRD 2,
MicroPort, Shanghai, China) powered to evaluate
noninferiority in clinical efﬁcacy outcomes.
METHODS
PATIENTS. Between October 2012 and June 2013, we
recruited adult patients with chronic, stable coronary
artery disease or acute coronary syndromes, including
myocardial infarction (MI) with or without ST-
segment elevation at 32 centers in China. Patients
were eligible if they were older than 18 years of age
and had at least 1 coronary lesion with stenosis >70%
in a vessel with reference diameter of 2.5 to 4.0 mm.
No restriction was placed on the total number of
treated lesions, treated vessels, lesion length, or
number of stents implanted. Patients with multivessel
disease must undergo complete revascularization
within 30 days using the same study stents if
needed. Exclusion criteria were known intolerance
to a study drug, metal alloys, or contrast media; life
expectancy <1 year; restenosed lesions; stent im-
plantation within 1 year; left ventricular ejection
fraction <40%; severe renal or hepatic dysfunction;
hemodynamic instability; planned surgery within 6
months after index procedure; childbearing potential
within 1 year; clinical indications of the inability
to tolerate dual-antiplatelet therapy (DAPT) for 12
months; inability to provide written informed con-
sent; and participation in another trial before reaching
the primary endpoint.The study complied with the provisions of
the Declaration of Helsinki, and the study
protocol was approved by the institutional
review board at each study center. All pa-
tients provided written informed consent.
STUDY DESIGN. The I-LOVE-IT 2 (Evaluate
Safety and Effectiveness of the Tivoli DES
and the Firebird DES for Treatment of Coro-
nary) trial was a prospective, multicenter,
randomized, assessor-blinded, noninferiority
study comparing BP-SES with DP-SES. Pa-
tients scheduled for percutaneous coronary
intervention (PCI) using DES were to be
enrolled with fewer exclusion criteria.
Patients were randomly assigned to un-
dergo PCI with either BP-SES or DP-SES in a 2:1
ratio. Patients who were randomized to BP-
SES group were additionally re-randomized
to a 6- or 12-month DAPT group in a 1:1 ratio (data
not available in this 1-year follow-up report). Ran-
domization was performed after angiogram by a Web-
based allocation system and was stratiﬁed by center.
Angiograms were reviewed by a blinded independent
core laboratory (CCRF, Beijing, China), and all adverse
events were adjudicated by a blinded clinical events
committee.
PROCEDURES. A comparison of speciﬁcations be-
tween BP-SES and DP-SES is shown in Table 1. Both are
low-proﬁle, thin-strut CoCr alloy stents with same
antiproliferative drug (7,8). Balloon angioplasty and
stent implantation were performed according to stan-
dard techniques; direct stenting (without previous
balloon dilation) was allowed. No mixture of type of
stents was permitted for a given patient unless the
operator was unable to insert the study stent, in which
case crossover to another nonstudy device of the
FIGURE 1 The I-LOVE-IT 2 Trial Patient Flow
A total of 2,790 patients were assessed for eligibility if they met the inclusion
and exclusion criteria, and 53 were excluded. Finally, 2,737 patients were
randomly assigned to either the BP-SES group or the DP-SES group in a 2:1
ratio. BP-SES ¼ biodegradable polymer sirolimus-eluting stent(s); DP-SES ¼
durable polymer sirolimus-eluting stent(s).
TABLE 2 Baseline Patient Characteristics
BP-SES
(n ¼ 1,829)
DP-SES
(n ¼ 908) p Value
Age, yrs 60.2  10.1 60.2  10.0 0.89
Male 1,243 (68.0) 636 (70.0) 0.27
Body mass index, kg/m2 25.2  3.0 25.1  3.0 0.64
Diabetes mellitus 414 (22.6) 193 (21.3) 0.41
Insulin-requiring diabetes 154 (8.4) 73 (8.0) 0.73
Hypertension 1,150 (62.9) 559 (61.6) 0.50
Hyperlipidemia 445 (24.3) 204 (22.5) 0.28
Family history of CAD 104 (5.7) 53 (5.8) 0.87
Smoking history 0.85
Current smoker 685 (37.5) 335 (36.9)
Ex-smoker 213 (11.7) 101 (11.1)
None 931 (50.9) 472 (52.0)
Previous myocardial infarction 301 (16.5) 151 (16.6) 0.91
Previous stroke 171 (9.4) 92 (10.1) 0.51
Peripheral arterial disease 23 (1.3) 4 (0.4) 0.04
Previous PCI 137 (7.5) 64 (7.1) 0.68
Previous CABG 8 (0.4) 6 (0.7) 0.57
Stable angina 269 (14.7) 126 (13.9) 0.56
Unstable angina 1,330 (72.7) 691 (76.1) 0.06
AMI within 24 h 86 (4.7) 51 (5.6) 0.30
LVEF, % 60.5  8.3 61.0  8.0 0.18
Values are mean  SD or n (%).
AMI ¼ acute myocardial infarction; CABG ¼ coronary artery bypass grafting;
CAD ¼ coronary artery disease; LVEF ¼ left ventricular ejection fraction; PCI ¼
percutaneous coronary intervention; other abbreviations as in Table 1.
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1354operator’s choice was possible. Staged procedures
were permitted, which were deﬁned as procedures
planned at the time of the index procedure and perfor-
med within 30 days with the same type of study stent.
In the case of unplanned revascularization procedures
requiring stent implantation, it was recommended
that physicians use the same type of study stent.
Procedural anticoagulation was achieved with
unfractionated heparin at a dose 70 to 100 IU per ki-
logram of body weight, and activated clotting time
was maintained at $250 s; the use of glycoprotein IIb/
IIIa inhibitors was left to operator’s discretion. A
loading dose of 300 mg aspirin and 300 mg clopidogrel
was administered before all procedures. All patients
were discharged with a prescription for at least 100 mg
aspirin indeﬁnitely and 75 mg clopidogrel for a mini-
mum of 6 months after the index procedure.
Qualitative and quantitative coronary angiography
(including SYNTAX [Synergy Between Percutaneous
Coronary Intervention With Taxus and Cardiac Sur-
gery] score and residual SYNTAX score) was centrally
evaluated at CCRF using QAngio XA Version 7.3
Analysis Software (Medis Medical Imaging System
Inc., Leiden, the Netherlands).
ENDPOINTS. The primary endpoint was 12-month
target lesion failure (TLF), a composite of cardiacdeath, target vessel myocardial infarction (TVMI),
or clinically indicated target lesion revasculari-
zation (TLR). Secondary endpoints included TLF
components, device/lesion/procedure success rates,
deﬁnite/probable stent thrombosis, and patient-
oriented composite endpoint, including composite
of all-cause death, all MI, and any revascularization.
We deﬁned cardiac death as any death due to an
evident cardiac cause, any death related to PCI,
unwitnessed death, or death of unknown causes.
Periprocedural MI in patients without infarction at
baseline was deﬁned as any increase in creatine ki-
nase concentration to more than double the normal
value (deﬁned according to the local laboratory’s
standard) with increased values of a conﬁrmatory
cardiac biomarker (creatine kinase-myocardial band
fraction or troponin) (9). Spontaneous infarction was
deﬁned as a typical rise and fall of troponin or crea-
tine kinase-myocardial band fraction with at least 1
of the following: ischemic symptoms, development
of pathological Q waves, ischemic electrocardiogra-
phic changes, or pathological ﬁndings of an acute
MI. For comparison with other trials using Academic
Research Consortium MI deﬁnitions, we also adjudi-
cated MI data according to Academic Research
Consortium deﬁnitions (10). TLR was deﬁned as
revascularization for a stenosis within the stent or
TABLE 3 Baseline Lesion Characteristics
BP-SES
(1,829 Patients,
2,495 Lesions)
DP-SES
(908 Patients,
1,235 Lesions) p Value
Target vessel disease extent 0.28
1-vessel 1,356 (74.1) 656 (72.2)
2-vessel 396 (21.7) 199 (21.9)
3-vessel 33 (1.8) 21 (2.3)
Left main disease 44 (2.4) 32 (3.5)
Baseline SYNTAX score 11.7  8.2 11.7  8.5 0.99
No. of target lesions 0.88
1 1,257 (68.7) 623 (68.6)
2 504 (27.6) 246 (27.1)
3 63 (3.4) 36 (4.0)
4 5 (0.3) 3 (0.3)
No. of target lesions per patient 1.35  0.56 1.36  0.57 0.88
Target vessel location 0.39
Left main artery 44 (1.8) 32 (2.6)
Left anterior descending artery 1,138 (45.6) 550 (44.5)
Left circumﬂex artery 563 (22.6) 281 (22.8)
Right coronary artery 750 (30.1) 372 (30.1)
ACC/AHA lesion classiﬁcation B2þC 2,083 (83.5) 1,051 (85.1) 0.21
Complex lesions 1,109 (44.4) 571 (46.2) 0.30
Bifurcation lesion 797 (31.9) 409 (33.1) 0.48
Ostial lesion 25 (1.0) 9 (0.7) 0.41
Total occlusion 306 (12.3) 150 (12.2) 0.92
Severely tortuous or angulated lesion 57 (2.3) 30 (2.4) 0.78
Moderate to heavy calciﬁcation 66 (2.7) 41 (3.3) 0.25
Pre-procedural TIMI ﬂow 0.37
0 307 (12.3) 151 (12.2)
1 44 (1.8) 18 (1.5)
2 133 (5.3) 51 (4.1)
3 2,011 (80.6) 1,015 (82.2)
Pre-procedural QCA
Reference vessel diameter, mm 2.79  0.47 2.79  0.44 0.85
Lesion length, mm 20.6  12.3 21.2  12.9 0.25
Minimal lumen diameter, mm 0.80  0.51 0.81  0.51 0.78
Diameter stenosis, % 71.6  16.9 71.6  16.6 0.96
Values are mean  SD or n (%). Complex lesions were deﬁned by presence of at least 1 of the
following lesion characteristics: unprotected left main coronary artery; bifurcation, ostial lesion;
total occlusion; severely tortuous or angulated lesion; and moderate to heavy calciﬁcation.
ACC/AHA ¼ American College of Cardiology/American Heart Association; QCA ¼ quantitative
coronary angiography; SYNTAX ¼ Synergy Between Percutaneous Coronary Intervention With
Taxus and Cardiac Surgery; TIMI ¼ thrombolysis in myocardial infarction; other abbreviations as in
Table 1.
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1355within the 5-mm borders adjacent to the stent. We
regarded revascularization of the target lesion and
vessel as clinically indicated if stenosis of any target
lesion or vessel was at least 50% of the diameter of the
vessel on the basis of quantitative coronary angiogra-
phy in the presence of objective evidence of ischemia
from noninvasive or invasive testing or symptoms.
We also regarded revascularization as clinically indi-
cated if stenosis was at least 70% of the diameter of
the vessel, irrespective of ischemic signs or symptoms.
Patients were followed by telephone or hospital
visit at 1, 6, 9, and 12 months and will continue to
undergo follow-up annually for 5 years.
STATISTICAL ANALYSIS. Based on previously re-
ported studies, sample size was calculated expecting
a 12-month event rate of 8.3% in both groups. The
pre-speciﬁed noninferiority margin for the primary
endpoint was 3.7%. With 1-sided type I error of 0.025,
2,631 patients (1,754 and 877 patients in BP-SES and
DP-SES groups, respectively) randomized in a 2:1 ratio
would yield at least 90% power to detect non-
inferiority. Allowing for up to 5% loss to follow-up, a
total of 2,790 subjects would need to be enrolled.
Noninferiority would be achieved if the upper limit of
the 1-sided 95% conﬁdence interval of the difference
is less than the margin.
Categorical variables are reported as counts and
percentages, and between-group differences were
assessed with chi-square or Fisher exact test. Con-
tinuous variables are presented as mean  SD and
were compared with a 2-sample t test. The Kaplan-
Meier method was used to calculate time to clinical
endpoints, and the log-rank test was used to compare
between-group differences. An exploratory Cox
regression analysis was used to identify demographic
and clinical factors predictive of the endpoint. Unless
otherwise speciﬁed, a 2-sided p value <0.05 was
considered to indicate statistical signiﬁcance. Statis-
tical analysis was performed using SAS software
version 9.1.3 (SAS Institute, Cary, North Carolina).
RESULTS
A total of 2,737 patients were randomly assigned to
receive either BP-SES (n ¼ 1,829) or DP-SES (n ¼ 908)
(Figure 1). Fourteen patients (0.5%) were lost to
follow-up before the 12-month cutoff date (11 and 3
patients in the BP-SES and DP-SES groups, respec-
tively). The 2 groups of patients were generally well
balanced in terms of baseline clinical and lesion
characteristics (Tables 2 and 3), except that there were
more patients with peripheral vascular disease in the
BP-SES group. A qualitative comparative analysis
and procedural results were similar in the 2 groups(Table 4). Procedural complications including throm-
bosis, dissection, slow/no ﬂow, severe spasm, and
perforation, occurred in 37 of 1,829 (2.0%) patients
in the BP-SES group and 21 of 908 (2.3%) patients in
the DP-SES group, respectively (p ¼ 0.62), and the
device/lesion/procedure success rates were relatively
high in both groups. A total of 853 of 909 patients
(93.8%) allocated to the 6-month DAPT group after
the BP-SES implantation actually stopped clopidogrel
at 6 months per the protocol. Therefore, a full 1-year
of clopidogrel plus aspirin treatment was followed
in all patients in the DP-SES group and in 50% of
patients in the BP-SES group.
TABLE 4 Procedural Characteristics and Results
BP-SES
(1,829 Patients,
2,495 Lesions)
DP-SES
(908 Patients,
1,235 Lesions) p Value
Transradial approach 1,696 (92.7) 849 (93.5) 0.46
Use of IVUS and/or OCT 60 (3.3) 28 (3.1) 0.78
Balloon pre-dilation 1,979 (79.3) 1,015 (82.2) 0.04
Stents per patient 1.70  0.86 1.75  0.89 0.19
Stents per lesion 1.26  0.50 1.29  0.52 0.12
$3 stents implanted per patient 287 (15.7) 162 (17.8) 0.15
Stent diameter, mm 3.05  0.44 3.04  0.40 0.35
Total stent length per patient, mm 41.1  24.4 42.7  24.8 0.11
Total stent length per lesion, mm 30.4  15.8 31.4  16.5 0.07
Post-dilation 1,282 (51.4) 571 (46.2) 0.003
Post-procedural TIMI ﬂow grade 3 2,482 (99.5) 1,228 (99.4) 0.86
Post-procedural QCA
Minimal lumen diameter, mm
In-stent 2.54  0.42 2.57  0.40 0.07
In-segment 2.38  0.46 2.39  0.44 0.36
Diameter stenosis, %
In-stent 8.4  5.2 8.4  5.5 0.94
In-segment 11.7  7.2 12.0  7.7 0.17
Residual SYNTAX score 3.3  5.1 3.2  5.6 0.74
Device success 3,116 (99.5) 1,589 (99.6) 0.62
Lesion success 2,478 (99.3) 1,228 (99.4) 0.67
Procedure success 1,752 (95.8) 868 (95.6) 0.81
Values are n (%) or mean  SD.
IVUS ¼ intravascular ultrasound; OCT ¼ optical coherence tomography; other abbreviations as
in Tables 1 and 3.
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1356At 12 months, the primary endpoint TLF difference
was 0.25% (95% conﬁdence interval: 1.67% to 2.17%)
between the BP-SES group (6.3%, 115 of 1,818) and the
DP-SES group (6.1%, 55 of 905), demonstrating non-
inferiority of BP-SES to DP-SES in terms of TLF with a
noninferiority margin of 3.7% (p for noninferiority ¼
0.0002) (Table 5, Figure 2A). Rates of all individual
components of TLF, including cardiac death (BP-SES
vs. DP-SES, 0.7% vs. 0.6%; p ¼ 0.62), TVMI (BP-SES vs.
DP-SES, 3.6% vs. 4.3%; p ¼ 0.39), and clinically indi-
cated TLR (BP-SES vs. DP-SES, 2.6% vs. 2.2%; p ¼ 0.50)
were similar between the 2 groups (Table 5, Figures 2B
to 2D). For the primary endpoint of TLF, the Breslow-
Day test was used to ﬁnd the variability between
centers. As the p value was 0.2357, center variability
can be ignored in the analysis. Furthermore, the
GLIMMIX procedure (SAS Institute) was used to model
the probability of TLF between the 2 groups, whereas
the center was regarded as a random effect (odds
ratio for BP-SES/DP-SES: 0.988 [95% conﬁdence in-
terval: 0.675 to 1.444]; p ¼ 0.9433).
For the secondary endpoint of patient-oriented
composite endpoint, there was no signiﬁcant differ-
ence between the BP-SES group and the DP-SES group
(BP-SES vs. DP-SES, 9.7% vs. 9.4%; p ¼ 0.81) (Table 5,
Figure 2E). Rates of all-cause death (BP-SES vs. DP-SES, 1.4% vs. 1.0%; p ¼ 0.40), all MI (BP-SES vs.
DP-SES, 4.2% vs. 4.6%; p ¼ 0.63), and any revascu-
larization (BP-SES vs. DP-SES, 5.1% vs. 4.9%; p ¼ 0.82)
were also similar between the 2 groups (Table 5). The
rates of deﬁnite/probable stent thrombosis were low
with no signiﬁcant difference between the 2 groups
(BP-SES vs. DP-SES, 0.4% vs. 0.6%; p ¼ 0.55) (Table 5,
Figure 2F). In addition, as the major contributor of
TVMI, the periprocedural MI was mainly caused by
abrupt closure or slow/no ﬂow during the PCI proce-
dure rather than stent thrombosis. Furthermore, the
number of patients reaching the primary endpoint in
each group did not differ signiﬁcantly between pre-
speciﬁed subgroups (Figure 3).
On multivariate Cox regression analyses, emergent
PCI for acute MI, baseline SYNTAX score, total stent
length per patient, and unsuccessfully treated lesion
were 4 independent predictors of TLF (Table 6). Stent
type was not an independent predictor of TLF.
DISCUSSION
The main ﬁnding of this prospective, randomized,
multicenter trial is that the BP-SES was noninferior to
the DP-SES when used in a population with minimal
exclusion criteria and assessed at 1-year follow-up.
Moreover, the primary composite endpoint of car-
diac death, TVMI, or clinically indicated TLR did not
differ signiﬁcantly between stent types nor did its
individual components or stent thrombosis rates.
This is the ﬁrst adequately powered trial to
compare BP with DP on similar CoCr stents both
eluting sirolimus. After the conduct of this study,
based on the observed TLF rate of 6.3% and the actual
number of subjects per group, there is 80% power
to exclude a 0.028 noninferiority margin (margin/
event ratio is 44.5%, same as originally planned).
Previous studies comparing BP-DES and DP-DES re-
ported conﬂicting results, perhaps in part due to
differing base stent platforms and eluting drugs
(6,11–14). In the SORT OUT V study, a BP-biolimus-
eluting stent (Nobori, Terumo, Tokyo, Japan) was
compared with a DP-SES (Cypher Select Plus, Cordis,
Johnson & Johnson, Warren, New Jersey) (6). In the
LEADERS trial, a stent eluting biolimus-A9 with a
biodegradable polylactic acid polymer (BioMatrix
Flex, Biosensors Inc., Newport Beach, California)
was evaluated against a DP-SES (Cypher SELECT,
Cordis, Miami Lakes, Florida) (11). Previous ex vivo
modeling demonstrated that strut thickness and
geometry along with optimal positioning are critical
factors in reducing thrombosis risk (15). Similarly,
previous clinical trials have demonstrated that stent
components such as strut thickness can play a role in
TABLE 5 Clinical Outcomes at 30 Days, 6 Months, and 12 Months in the
Intention-to-Treat Population
BP-SES
(n ¼ 1,829)
DP-SES
(n ¼ 908) p Value
30 days
Target lesion failure 61 (3.3) 39 (4.3) 0.21
All-cause death 5 (0.3) 1 (0.1) 0.67
Cardiac death 2 (0.1) 1 (0.1) 1.00
All myocardial infarction 67 (3.7) 38 (4.2) 0.50
Q-wave myocardial infarction 10 (0.6) 5 (0.6) 1.00
Non–Q-wave myocardial infarction 57 (3.1) 33 (3.6) 0.47
Target vessel myocardial infarction 59 (3.2) 36 (4.0) 0.32
Any revascularization 2 (0.1) 6 (0.7) 0.02
Target vessel revascularization 2 (0.1) 5 (0.6) 0.04
Target lesion revascularization 2 (0.1) 5 (0.6) 0.04
Clinically indicated target lesion
revascularization
2 (0.1) 5 (0.6) 0.04
Patient-oriented composite endpoint 70 (3.8) 42 (4.6) 0.32
6 months
Target lesion failure 79 (4.3) 47 (5.2) 0.31
All-cause death 13 (0.7) 6 (0.7) 0.88
Cardiac death 7 (0.4) 4 (0.4) 0.76
All myocardial infarction 72 (3.9) 41 (4.5) 0.47
Q-wave myocardial infarction 12 (0.7) 7 (0.8) 0.73
Non–Q-wave myocardial infarction 60 (3.3) 34 (3.7) 0.53
Target vessel myocardial infarction 63 (3.4) 38 (4.2) 0.33
Any revascularization 29 (1.6) 21 (2.3) 0.18
Target vessel revascularization 17 (0.9) 11 (1.2) 0.49
Target lesion revascularization 15 (0.8) 11 (1.2) 0.32
Clinically indicated target lesion
revascularization
15 (0.8) 11 (1.2) 0.32
Patient-oriented composite endpoint 105 (5.7) 61 (6.7) 0.31
12 months (n ¼ 1,818) (n ¼ 905)
Target lesion failure 115 (6.3) 55 (6.1) 0.80
All-cause death 25 (1.4) 9 (1.0) 0.40
Cardiac death 13 (0.7) 5 (0.6) 0.62
All myocardial infarction 77 (4.2) 42 (4.6) 0.63
Q-wave myocardial infarction 14 (0.8) 8 (0.9) 0.75
Non-Q-wave myocardial infarction 64 (3.5) 34 (3.8) 0.75
Target vessel myocardial infarction 66 (3.6) 39 (4.3) 0.39
Any revascularization 92 (5.1) 44 (4.9) 0.82
Target vessel revascularization 58 (3.2) 25 (2.8) 0.54
Target lesion revascularization 48 (2.6) 21 (2.3) 0.62
Clinically indicated target lesion
revascularization
48 (2.6) 20 (2.2) 0.50
Patient-oriented composite endpoint 176 (9.7) 85 (9.4) 0.81
Deﬁnite/probable stent thrombosis (365 days) 7 (0.4) 5 (0.6) 0.55
Deﬁnite stent thrombosis 3 (0.2) 4 (0.4) 0.23
Probable stent thrombosis 4 (0.2) 1 (0.1) 1.00
Acute (0–1 day) 3 (0.2) 2 (0.2) 0.67
Subacute (2–30 days) 3 (0.2) 2 (0.2) 0.67
Late (31–365 days) 1 (0.1) 1 (0.1) 0.55
Values are n (%). Patient-oriented composite endpoint was deﬁned as a composite of all-cause
death, all myocardial infarction, and any revascularization.
Abbreviations as in Table 1.
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1357varied clinical outcomes of stent platforms (16).
Therefore, similar stent platforms are important in
the design of studies evaluating the differential
efﬁcacy of different polymers. Furthermore, the
BP-DES platform in previous studies (Nobori and
BioMatrix Flex) consists of stainless steel with rela-
tively thick struts (120 mm) (17). In comparison, the
BP-SES in our study had a thinner strut thickness
of 80 mm. Future efforts to achieve better safety with
BP-DES need to focus on both reducing stent strut
and polymer thickness.
One of the important results from our study is
depicted in the TLF Kaplan-Meier curve (Figure 2A).
First, these results are consistent with a previous
meta-analysis (18) that showed that although BP-DES
are superior to DP-DES in terms of inhibition of neo-
intimal regrowth, no obvious beneﬁt on harder end-
points such as mortality, MI, and revascularization
rates is apparent. Second, the 2 survival curves
separated before 6-month follow-up, but approached
each other after 6 months. Because only half of the
BP-SES group received clopidogrel for longer than 6
months (per the protocol-driven subrandomization),
it is possible that the lower level of DAPT use in
this group may have afforded an increase in event
rates within the 6- to 12-month interval of follow-up.
This will be appropriately investigated when out-
comes data in relation to the DAPT randomization
become available. However, long-term follow-up is
warranted.
The rates of stent thrombosis were low in both
groups, which is not surprising and consistent with a
previous meta-analysis (19) showing that CoCr-DES
reduced stent thrombosis even when compared with
bare metal stents. Previous studies showed a statis-
tically signiﬁcant and likely clinically important risk
reduction for deﬁnite stent thrombosis in favor of BP-
DES compared with DP-DES at long-term follow-up
(5). For example, the 5-year results in the LEADERS
trial showed that BP-DES was associated with a sig-
niﬁcant reduction in very late (>1 year) deﬁnite stent
thrombosis (20). Therefore, long-term follow-up in
the study is needed to also clarify beneﬁt of BP-DES
on the stent thrombosis rate. Additionally, the
optimal duration of DAPT after BP-DES implantation
remains controversial. From a post-hoc analysis, we
recently found that prolonged DAPT (>6 months)
after BP-DES implantation increases the risk of
bleeding and is associated with adverse cardiac
events at 1-year follow-up (21). Long-term follow-up
will provide valuable data from 6- versus 12-month
DAPT randomization in the study.
STUDY LIMITATIONS. First, we enrolled only part of
the total PCI population at enrolling centers ratherthan consecutive patients, and we cannot rule out
some selection bias. However, the baseline SYNTAX
score of enrolled patients in this study compared
favorably with that in previous all-comer trials (11,22),
FIGURE 2 Kaplan-Meier Cumulative Event Curves Through 1 Year
Kaplan-Meier curves of 1-year outcomes for overall patients who received BP-SES (blue line) or DP-SES (red line), including primary endpoint
TLF and components (A to D), secondary endpoint PoCE (patient oriented composite endpoint, a composite of all cause death, all myocardial
infarction, and any revascularization) (E), and deﬁnite/probable stent thrombosis (F). Abbreviations as in Figure 1.
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FIGURE 3 Subgroup Analysis of the Primary Endpoint
Primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial infarction, and clinically indicated target
lesion revascularization. CI ¼ conﬁdence interval; PCI ¼ percutaneous coronary intervention; AMI ¼ acute myocardial infarction; TIMI ¼
Thrombolysis In Myocardial Infarction; other abbreviations as in Figure 1.
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1359and low residual SYNTAX scores may partly explain
the lower event rates in this trial. Therefore, we
consider that our ﬁndings are highly generalizable
to patients in everyday clinical practice. Second, theTABLE 6 Independent Predictors of 1-Year TLF by Multivariable
Cox Regression Analysis
Variable Hazard Ratio (95% CI) p Value
Emergent PCI for AMI 2.455 (1.435–4.198) 0.001
Baseline SYNTAX score 1.029 (1.010–1.047) 0.002
Total stent length per patient 1.009 (1.003–1.015) 0.003
Lesion unsuccessful 4.324 (1.876–9.967) 0.0006
CI ¼ conﬁdence interval; TLF ¼ target lesion failure; other abbreviations as n
Tables 2 and 3.composite endpoints were used as primary endpoints
in the study, which have well-recognized limitations
that arise from the common practice of weighting all
endpoint components equally, irrespective of their
relative impact on the life of the patient (23). Third, the
study was not sufﬁciently powered to evaluate the
safety endpoints at 12 months, especially stent
thrombosis, warranting longer follow-up or larger tri-
als. Fourth, we used the old universal deﬁnition of
periprocedural MI, which may overestimate the
occurrence of TVMI. A recent deﬁnition of universal
MI was an infarction with >5-fold cardiac enzyme in-
creases. Last, although baseline characteristic bias
was well controlled in this randomized trial, there are
some differences in procedural characteristics, for
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1360example, the rates of balloon pre-dilation and post-
dilation, which might reﬂect minor difference
between the 2 stent platforms. However, those differ-
ences were not the predictors of the primary endpoint.
CONCLUSIONS
The I-LOVE-IT 2 trial demonstrated that the BP-SES
is noninferior in terms of efﬁcacy to the DP-SES in
clinical practice. Whether the BP-SES improves safety
with respect to lowering the incidence of stent
thrombosis compared with DP-SES remains to be
shown in longer term follow-up of this trial or in
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APPENDIX For the I-LOVE-IT 2 trial
organization and the contributions of the
participating centers, please see the online
versions of this article.
